

ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/I10490A5077EN.html>

Date: April 2021

Pages: 48

Price: US\$ 125.00 (Single User License)

ID: I10490A5077EN

Abstracts

ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGIC936 the company's program candidate for a range of solid tumors; and IMGN151, its next generation anti-FRa candidate in preclinical development stage. ImmunoGen Inc incorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc Key Recent Developments

Feb 12,2021: ImmunoGen Reports Recent Progress and 2020 Financial Results

Nov 06,2020: ImmunoGen reports recent progress and third quarter 2020 financial results

Jul 31,2020: ImmunoGen reports recent progress and second quarter 2020 financial results

Jul 20,2020: ImmunoGen appoints Susan Altschuller, PhD as senior vice president and chief financial officer

Jun 01,2020: ImmunoGen appoints Stacy Coen as Senior Vice President and Chief Business Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ImmunoGen Inc - Key Facts
ImmunoGen Inc - Key Employees
ImmunoGen Inc - Key Employee Biographies
ImmunoGen Inc - Major Products and Services
ImmunoGen Inc - History
ImmunoGen Inc - Company Statement
ImmunoGen Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
ImmunoGen Inc - Business Description
ImmunoGen Inc - Corporate Strategy
ImmunoGen Inc - SWOT Analysis
SWOT Analysis - Overview
ImmunoGen Inc - Strengths
ImmunoGen Inc - Weaknesses
ImmunoGen Inc - Opportunities
ImmunoGen Inc - Threats
ImmunoGen Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ImmunoGen Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 12, 2021: ImmunoGen Reports Recent Progress and 2020 Financial Results

Nov 06, 2020: ImmunoGen reports recent progress and third quarter 2020 financial results

Jul 31, 2020: ImmunoGen reports recent progress and second quarter 2020 financial results

Jul 20, 2020: ImmunoGen appoints Susan Altschuller, PhD as senior vice president and chief financial officer

Jun 01, 2020: ImmunoGen appoints Stacy Coen as Senior Vice President and Chief Business Officer

May 01, 2020: ImmunoGen reports recent progress and first quarter 2020 financial results

Feb 14, 2020: ImmunoGen reports recent progress and 2019 financial results

Jan 22, 2020: ImmunoGen announces proposed public offering of common stock

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

ImmunoGen Inc, Key Facts
ImmunoGen Inc, Key Employees
ImmunoGen Inc, Key Employee Biographies
ImmunoGen Inc, Major Products and Services
ImmunoGen Inc, History
ImmunoGen Inc, Subsidiaries
ImmunoGen Inc, Key Competitors
ImmunoGen Inc, Ratios based on current share price
ImmunoGen Inc, Annual Ratios
ImmunoGen Inc, Annual Ratios (Cont...1)
ImmunoGen Inc, Interim Ratios
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ImmunoGen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ImmunoGen Inc, Performance Chart (2016 - 2020)

ImmunoGen Inc, Ratio Charts

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/l10490A5077EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l10490A5077EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970